Brazil · Delayed Price · Currency is BRL Dexco Statistics
Total Valuation
Dexco has a market cap or net worth of BRL 4.34 billion. The enterprise value is 10.92 billion.
| Market Cap | 4.34B |
| Enterprise Value | 10.92B |
Important Dates
The next confirmed earnings date is Thursday, August 6, 2026.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Dexco has 907.65 million shares outstanding. The number of shares has increased by 1.06% in one year.
| Current Share Class | 907.65M |
| Shares Outstanding | 907.65M |
| Shares Change (YoY) | +1.06% |
| Shares Change (QoQ) | -3.59% |
| Owned by Insiders (%) | 19.49% |
| Owned by Institutions (%) | 31.00% |
| Float | 278.97M |
Valuation Ratios
The trailing PE ratio is 505.31 and the forward PE ratio is 9.94. Dexco's PEG ratio is 0.07.
| PE Ratio | 505.31 |
| Forward PE | 9.94 |
| PS Ratio | 0.52 |
| PB Ratio | 0.59 |
| P/TBV Ratio | 0.71 |
| P/FCF Ratio | 10.70 |
| P/OCF Ratio | 3.34 |
| PEG Ratio | 0.07 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.28, with an EV/FCF ratio of 26.92.
| EV / Earnings | 1,271.47 |
| EV / Sales | 1.31 |
| EV / EBITDA | 5.28 |
| EV / EBIT | 13.20 |
| EV / FCF | 26.92 |
Financial Position
The company has a current ratio of 2.05, with a Debt / Equity ratio of 1.27.
| Current Ratio | 2.05 |
| Quick Ratio | 1.48 |
| Debt / Equity | 1.27 |
| Debt / EBITDA | 4.97 |
| Debt / FCF | 23.17 |
| Interest Coverage | 0.66 |
Financial Efficiency
Return on equity (ROE) is 1.05% and return on invested capital (ROIC) is 4.76%.
| Return on Equity (ROE) | 1.05% |
| Return on Assets (ROA) | 2.16% |
| Return on Invested Capital (ROIC) | 4.76% |
| Return on Capital Employed (ROCE) | 3.96% |
| Weighted Average Cost of Capital (WACC) | 7.76% |
| Revenue Per Employee | 587,905 |
| Profits Per Employee | 603 |
| Employee Count | 14,228 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 3.66 |
Taxes
| Income Tax | -114.64M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -3.36% in the last 52 weeks. The beta is 0.44, so Dexco's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | -3.36% |
| 50-Day Moving Average | 5.11 |
| 200-Day Moving Average | 5.05 |
| Relative Strength Index (RSI) | 46.77 |
| Average Volume (20 Days) | 1,986,885 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Dexco had revenue of BRL 8.36 billion and earned 8.59 million in profits. Earnings per share was 0.01.
| Revenue | 8.36B |
| Gross Profit | 2.01B |
| Operating Income | 649.46M |
| Pretax Income | -38.28M |
| Net Income | 8.59M |
| EBITDA | 1.81B |
| EBIT | 649.46M |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
The company has 3.13 billion in cash and 9.40 billion in debt, with a net cash position of -6.12 billion or -6.74 per share.
| Cash & Cash Equivalents | 3.13B |
| Total Debt | 9.40B |
| Net Cash | -6.12B |
| Net Cash Per Share | -6.74 |
| Equity (Book Value) | 7.37B |
| Book Value Per Share | 7.62 |
| Working Capital | 3.44B |
Cash Flow
In the last 12 months, operating cash flow was 1.30 billion and capital expenditures -891.52 million, giving a free cash flow of 405.60 million.
| Operating Cash Flow | 1.30B |
| Capital Expenditures | -891.52M |
| Depreciation & Amortization | 1.17B |
| Net Borrowing | 1.07B |
| Free Cash Flow | 405.60M |
| FCF Per Share | 0.45 |
Margins
Gross margin is 24.09%, with operating and profit margins of 7.76% and 0.10%.
| Gross Margin | 24.09% |
| Operating Margin | 7.76% |
| Pretax Margin | -0.46% |
| Profit Margin | 0.10% |
| EBITDA Margin | 21.69% |
| EBIT Margin | 7.76% |
| FCF Margin | 4.85% |
Dividends & Yields
Dexco does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.06% |
| Shareholder Yield | -1.06% |
| Earnings Yield | 0.20% |
| FCF Yield | 9.35% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Dexco is 7.66, which is 58.26% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 7.66 |
| Price Target Difference | 58.26% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 6.11% |
| EPS Growth Forecast (3Y) | 80.47% |
Stock Splits
The last stock split was on December 26, 2025. It was a forward split with a ratio of 1.12.
| Last Split Date | Dec 26, 2025 |
| Split Type | Forward |
| Split Ratio | 1.12 |
Scores
Dexco has an Altman Z-Score of 1.07 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.07 |
| Piotroski F-Score | 6 |